Xenetic Biosciences Stock Current Ratio
| XBIO Stock | USD 4.11 0.10 2.49% |
Xenetic Biosciences fundamentals help investors to digest information that contributes to Xenetic Biosciences' financial success or failures. It also enables traders to predict the movement of Xenetic Stock. The fundamental analysis module provides a way to measure Xenetic Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xenetic Biosciences stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 11.84 | 12.43 |
Xenetic | Current Ratio |
Xenetic Biosciences Company Current Ratio Analysis
Xenetic Biosciences' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Xenetic Biosciences Current Ratio | 12.02 X |
Most of Xenetic Biosciences' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xenetic Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Xenetic Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Xenetic Biosciences is extremely important. It helps to project a fair market value of Xenetic Stock properly, considering its historical fundamentals such as Current Ratio. Since Xenetic Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Xenetic Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Xenetic Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Xenetic Current Ratio Historical Pattern
Today, most investors in Xenetic Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Xenetic Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current ratio growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Xenetic Biosciences current ratio as a starting point in their analysis.
Xenetic Biosciences Current Ratio |
| Timeline |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Xenetic Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Xenetic Biosciences has a Current Ratio of 12.02 times. This is 313.06% higher than that of the Biotechnology sector and 71.71% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Xenetic Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Xenetic Biosciences' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Xenetic Biosciences could also be used in its relative valuation, which is a method of valuing Xenetic Biosciences by comparing valuation metrics of similar companies.Xenetic Biosciences is currently under evaluation in current ratio category among its peers.
Xenetic Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Xenetic Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Xenetic Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Xenetic Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (1.86) % | ||||
| Operating Margin | (1.84) % | ||||
| Current Valuation | (507.28 K) | ||||
| Shares Outstanding | 1.54 M | ||||
| Shares Owned By Insiders | 19.05 % | ||||
| Shares Owned By Institutions | 2.09 % | ||||
| Number Of Shares Shorted | 14.83 K | ||||
| Price To Earning | (1.81) X | ||||
| Price To Book | 0.90 X | ||||
| Price To Sales | 2.51 X | ||||
| Revenue | 2.54 M | ||||
| Gross Profit | 1.16 M | ||||
| EBITDA | (4.52 M) | ||||
| Net Income | (4.13 M) | ||||
| Cash And Equivalents | 14.93 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 809.59 K | ||||
| Current Ratio | 12.02 X | ||||
| Book Value Per Share | 6.36 X | ||||
| Cash Flow From Operations | (4.11 M) | ||||
| Short Ratio | 0.77 X | ||||
| Earnings Per Share | (2.66) X | ||||
| Target Price | 40.0 | ||||
| Beta | 2.26 | ||||
| Market Capitalization | 6.33 M | ||||
| Total Asset | 10.61 M | ||||
| Retained Earnings | (193.23 M) | ||||
| Working Capital | 8.78 M | ||||
| Current Asset | 1.21 M | ||||
| Current Liabilities | 4.97 M | ||||
| Net Asset | 10.61 M |
About Xenetic Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xenetic Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xenetic Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xenetic Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Xenetic Biosciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Xenetic Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xenetic Biosciences will appreciate offsetting losses from the drop in the long position's value.Moving against Xenetic Stock
The ability to find closely correlated positions to Xenetic Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Xenetic Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Xenetic Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Xenetic Biosciences to buy it.
The correlation of Xenetic Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Xenetic Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Xenetic Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Xenetic Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Xenetic Biosciences Piotroski F Score and Xenetic Biosciences Altman Z Score analysis. To learn how to invest in Xenetic Stock, please use our How to Invest in Xenetic Biosciences guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenetic Biosciences. If investors know Xenetic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenetic Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.66) | Revenue Per Share 1.638 | Quarterly Revenue Growth 0.116 | Return On Assets (0.29) | Return On Equity (0.49) |
The market value of Xenetic Biosciences is measured differently than its book value, which is the value of Xenetic that is recorded on the company's balance sheet. Investors also form their own opinion of Xenetic Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Xenetic Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenetic Biosciences' market value can be influenced by many factors that don't directly affect Xenetic Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenetic Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenetic Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenetic Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.